Dendritic cell subpopulations in nasopharyngeal cancer

Nilsson,Johan  S.; Abolhalaj,Milad; Lundberg,Kristina; Lindstedt,Malin; Greiff,Lennart

doi:10.3892/ol.2018.9835

Dendritic cell subpopulations in nasopharyngeal cancer

Authors:
- Johan S. Nilsson
- Milad Abolhalaj
- Kristina Lundberg
- Malin Lindstedt
- Lennart Greiff
View Affiliations

Affiliations: Department of Otorhinolaryngology, Head and Neck Surgery, Skåne University Hospital, Lund SE‑221 85, Sweden, Department of Immunotechnology, Lund University, Lund SE‑221 00, Sweden
Published online on: December 14, 2018 https://doi.org/10.3892/ol.2018.9835
Pages: 2557-2561

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasopharyngeal cancer (NPC) is associated with Epstein‑Barr virus (EBV) and EBV antigen may be utilized for therapeutic purposes, including targeting of dendritic cells (DCs). Although DCs may be present in NPC, the information is limited and not up‑to‑date with current knowledge on DC subsets. In the present study, biopsies from untreated NPC were obtained and subjected to multicolor flow‑cytometry focusing on DC subtype markers: CD123 for plasmacytoid DCs (pDCs); and CD1c and CD141 for myeloid DCs (mDCs). Furthermore, subset‑specific expression of the C‑lectin receptor (CLR) CD207 (also termed langerin) was assessed. pDCs and mDCs were detected in the NPC lesions, contributing to a frequency mean average of 0.78% of CD45+ leukocytes in situ. Different subpopulations, previously not described in NPC, were observed, including: CD123+ pDCs; CD1c+ mDCs; CD141+ mDCs; and CD1c‑CD141‑ mDCs. A high frequency of CD1c+ mDCs expressing CD207 was observed, compared with other subsets. In conclusion, different DC subsets are present in NPC lesions. The CLR CD207, a selective endocytic marker on CD1c+ mDCs, may be targeted for therapeutic purposes to facilitate cross‑presentation of antigens and aid cell‑mediated antitumor effects.

View Figures

View References

1	Chua ML, Wee JT, Hui EP and Chan AT: Nasopharyngeal carcinoma. Lancet. 387:1012–1024. 2016. View Article : Google Scholar : PubMed/NCBI
2	Lee AW, Sze WM, Au JS, Leung SF, Leung TW, Chua DT, Zee BC, Law SC, Teo PM, Tung SY, et al: Treatment results for nasopharyngeal carcinoma in the modern era: The Hong Kong experience. Int J Radiat Oncol Biol Phys. 61:1107–1116. 2005. View Article : Google Scholar : PubMed/NCBI
3	Zackrisson B, Mercke C, Strander H, Wennerberg J and Cavallin-Ståhl E: A systematic overview of radiation therapy effects in head and neck cancer. Acta Oncol. 42:443–461. 2003. View Article : Google Scholar : PubMed/NCBI
4	Chua D, Huang J, Zheng B, Lau SY, Luk W, Kwong DL, Sham JS, Moss D, Yuen KY, Im SW and Ng MH: Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer. 94:73–80. 2001. View Article : Google Scholar : PubMed/NCBI
5	Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C, et al: Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol. 23:8942–8949. 2005. View Article : Google Scholar : PubMed/NCBI
6	Lin CL, Lo WF, Lee TH, Ren Y, Hwang SL, Cheng YF, Chen CL, Chang YS, Lee SP, Rickinson AB and Tam PK: Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8⁺ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Res. 62:6952–6958. 2002.PubMed/NCBI
7	Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, Moss DJ, Coman W, Chan KH, Nicholls J, et al: Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 72:1116–1125. 2012. View Article : Google Scholar : PubMed/NCBI
8	Collin M and Haniffa M: Dendritic cells and dendritic cell subsets. Encyclopedia of Immunobiology. Academic Press; Oxford: pp. 345–352. 2016, View Article : Google Scholar
9	Lundberg K, Rydnert F, Greiff L and Lindstedt M: Human blood dendritic cell subsets exhibit discriminative pattern recognition receptor profiles. Immunology. 142:279–288. 2014. View Article : Google Scholar : PubMed/NCBI
10	Joffre OP, Segura E, Savina A and Amigorena S: Cross-presentation by dendritic cells. Nat Rev Immunol. 12:557–569. 2012. View Article : Google Scholar : PubMed/NCBI
11	Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y, Duvert-Frances V, Vincent C, Schmitt D, Davoust J, et al: Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity. 12:71–81. 2000. View Article : Google Scholar : PubMed/NCBI
12	Idoyaga J, Cheong C, Suda K, Suda N, Kim JY, Lee H, Park CG and Steinman RM: Cutting edge: Langerin/CD207 receptor on dendritic cells mediates efficient antigen presentation on MHC I and II products in vivo. J Immunol. 180:3647–3650. 2008. View Article : Google Scholar : PubMed/NCBI
13	Thomas JA, Iliescu V, Crawford DH, Ellouz R, Cammoun M and de-Thé G: Expression of HLA-DR antigens in nasopharyngeal carcinoma: An immunohistological analysis of the tumour cells and infiltrating lymphocytes. Int J Cancer. 33:813–819. 1984. View Article : Google Scholar : PubMed/NCBI
14	Braz-Silva PH, Vitale S, Butori C, Guevara N, Santini J, Magalhaes M, Hofman P and Doglio A: Specific infiltration of langerin-positive dendritic cells in EBV-infected tonsil, Hodgkin lymphoma and nasopharyngeal carcinoma. Int J Cancer. 128:2501–2508. 2011. View Article : Google Scholar : PubMed/NCBI
15	Hammar S, Bockus D, Remington F and Bartha M: The widespread distribution of Langerhans cells in pathologic tissues: An ultrastructural and immunohistochemical study. Hum Pathol. 17:894–905. 1986. View Article : Google Scholar : PubMed/NCBI
16	Lauriola L, Michetti F, Sentinelli S and Cocchia D: Detection of S-100 labelled cells in nasopharyngeal carcinoma. J Clin Pathol. 37:1235–1238. 1984. View Article : Google Scholar : PubMed/NCBI
17	Ma CX, Jia TC, Li XR, Zhand ZF and Yiao CB: Langerhans cells in nasopharyngeal carcinoma in relation to prognosis. In Vivo. 9:225–229. 1995.PubMed/NCBI
18	Zong YS, Zhang CQ, Zhang F, Ruan JB, Chen MY, Feng KT and Yu ZF: Infiltrating lymphocytes and accessory cells in nasopharyngeal carcinoma. Jpn J Cancer Res. 84:900–905. 1993. View Article : Google Scholar : PubMed/NCBI
19	Thompson LD: Update on nasopharyngeal carcinoma. Head Neck Pathol. 1:81–86. 2007. View Article : Google Scholar : PubMed/NCBI
20	Sobin LH, Gospodarowicz MK and Wittekind C: UICC: TNM Classification of Malignant Tumours. 7th. Wiley-Blackwell; New Jersey: 2009
21	Segura E, Durand M and Amigorena S: Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med. 210:1035–1047. 2013. View Article : Google Scholar : PubMed/NCBI
22	Chang CS, Chang JH, Hsu NC, Lin HY and Chung CY: Expression of CD80 and CD86 costimulatory molecules are potential markers for better survival in nasopharyngeal carcinoma. BMC Cancer. 7:882007. View Article : Google Scholar : PubMed/NCBI
23	Yin W, Duluc D, Joo H and Oh S: Dendritic cell targeting vaccine for HPV-associated cancer. Cancer Cell Microenviron. 3:e14822016.PubMed/NCBI
24	Villani AC, Satija R, Reynolds G, Sarkizova S, Shekhar K, Fletcher J, Griesbeck M, Butler A, Zheng S, Lazo S, et al: Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science. 356(pii): eaah45732017. View Article : Google Scholar : PubMed/NCBI
25	Abolhalaj M, Askmyr D, Sakellariou CA, Lundberg K, Greiff L and Lindstedt M: Profiling dendritic cell subsets in head and neck squamous cell tonsillar cancer and benign tonsils. Sci Rep. 8:80302018. View Article : Google Scholar : PubMed/NCBI